Hydrogen protects against liver injury during CO2 pneumoperitoneum in rats.
Mingzi Chen, Lihong Jiang, Yue Li, Ge Bai, Jinghua Zhao, Ming Zhang, Jiantao Zhang · Oncotarget · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In rats, mDA concentration significantly increased in P15 group compared with C group at 2 h and 6 h, while its concentration is significantly reduced in the H₂ group compared with the CO₂ pneumoperitoneum group ( P < 0.05, Figure 2A and 2D ). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how subcutaneous hydrogen gas injection affected the outcomes measured in rats. MDA concentration significantly increased in P15 group compared with C group at 2 h and 6 h, while its concentration is significantly reduced in the H₂ group compared with the CO₂ pneumoperitoneum group ( P < 0.05, Figure 2A and 2D ).
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 90 min. MDA concentration significantly increased in P15 group compared with C group at 2 h and 6 h, while its concentration is significantly reduced in the H₂ group compared with the CO₂ pneumoperitoneum group ( P < 0.05, Figure 2A and 2D ). The authors concluded that subcutaneous hydrogen injection could exert a protective effect against liver injury during CO₂ pneumoperitoneum through reducing oxidative stress, cellular apoptosis and inflammatory cytokine release. Figure 2 Hypodermic injection of hydrogen gas protected against liver oxidative stress injury induced by pneumoperitoneum ( A, B and C ) The MDA, SOD and GSH levels in serum. ( D, E and F ) The MDA, SOD and GSH levels in liver tissue.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The reported sample size was 5. The study used a preclinical animal experiment. The hydrogen delivery method was subcutaneous hydrogen gas injection. The reported treatment duration was 90 min.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.